Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences practice is dedicated to providing tailored solutions to help maximize value and drive towards equitable access to life-saving treatments.
ASCO 2024 review: The benefits and barriers of biomarkers in oncology
Biomarkers: what do we mean? – The term “biomarkers” can be broadly clustered into four categories: molecular, histologic, radiographic and physiological. –...